Medicortex Finland Oyj

Medicortex Finland Oy Announces the Advancement in Clinical Trial for Detection of Mild Traumatic Brain Injury in Children

TURKU, Finland. Medicortex Finland Oy announces achievement of the halfway in the clinical trial for detection of mild traumatic brain injury (TBI) and concussion in children and adolescents. Company's third clinical trial is being conducted at Satasairaala hospital in Finland. About 50% of the target number of head injury patients and healthy controls have already been enrolled in the study which started in March this year.

Medicortex Finland Oy on saavuttanut puolivälin lasten ja nuorten tapaturmaisten aivovammojen diagnostiikkaan liittyvässä kliinisessä tutkimuksessa. Yrityksen kolmas kliininen tutkimus toteutetaan Satasairaalassa Porissa. Tavoitemäärään nähden noin 50% aivotärähdyspotilaista ja terveistä verrokeista on jo saatu tämän vuoden maaliskuussa alkaneeseen tutkimukseen.

The onset of the corona pandemic somewhat retarded the rate of patient enrolment in the early phase of the study as the hospital was put on standby to nurse infected patients, and the number of eligible head injury patients went down because of suspension of several everyday goings and leisure activities. Since the late spring the situation has gradually normalized and we are receiving near regular number of patients in the hospital and enrolling patients at a steady rate in the study, said Dr. Sari Malmi, the Principal Investigator of the study and the Head of Pediatric Surgery Department.

“A diagnostic kit for rapid detection of mild TBI in children is important. It will satisfy the pressing need to improve the detection of brain injury in children who suffered a head injury” said Dr. Mårten Kvist, Medical Director of Medicortex Finland Oy. The rapid diagnostic kit ProbTBI, currently being developed by Medicortex, will help to diagnose brain injury especially in patients who do not show visible symptoms of brain damage which is frequently the case in concussion and mild injury.

Satasairaala hospital in Pori is the main hospital in Satakunta province with the first level pediatric emergency department and expertise in the TBI management. Body fluid samples are being collected from 30 young patients (0 - 17 years) with suspected mild TBI and from 30 age-matched healthy volunteers. The samples will be studied with respect to a specific biomarker signature following a head injury.

"ProbTBI™ will be a highly innovative diagnostic kit for rapid detection of concussion. Children in particular will benefit from it since they can be refrained from radiation or sedation which are needed for the CT scan of the head, as well as from an exposure to other sick patients in the hospital "said Dr. Adrian Harel, CEO of Medicortex. “Participation of the young patients shortly after a head injury is a challenge, but we have a committed and skilled clinical team working with us in the hospital” Dr. Harel adds.

In this clinical trial, Medicortex intends to collect a sufficient number of pediatric samples in order to test the applicability of the brain injury test in children, an expected continuation for previously proven clinical performance in adults. The clinical trial is posted at the public database with identifierNCT04288167.

Medicortex Finland Oy is engaged in the development of a first-of-its-kind diagnostic kit for rapid detection of concussion and mild TBI from non-invasive body fluid samples. The Company has the technology to capture biomarkers from urine and saliva and to develop them into an affordable diagnostic tool. The patent portfolio held by Medicortex secures exclusivity to develop the product. More information about TBI and its detection is available on the Company's website at




Medicortex Finland Oy
Dr. Adrian Harel - CEO
Tel. +358 (0) 400 488 817


About Medicortex Finland Oyj

Medicortex Finland Oyj
Medicortex Finland Oyj
Itäinen Pitkäkatu 4 B
20520 TURKU

Medicortex Finland Oyj ( on tutkimuslähtöinen lääkealan yritys, joka kehittää uudenlaista diagnostista menetelmää perustuen biomerkkiaineisiin.

Subscribe to releases from Medicortex Finland Oyj

Subscribe to all the latest releases from Medicortex Finland Oyj by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Medicortex Finland Oyj

Medicortex Finland Plc appointing a new advisor1.12.2022 09:30:00 EET | Press release

Medicortex Finland Plc, a biotechnology company located in Turku, Finland, with a proprietary biomarker technology for detection of traumatic brain injury (TBI) and numerous other pipeline product candidates, announced today appointment of Professor Mika Hannula (DSc Tech) as a new member in company’s Scientific and Clinical Advisory Board (SAB). Professor Hannula supplements the team of scientists and clinicians with his diverse expertise in academic research management.

Medicortex Finland Oyj sopimukseen 2 miljoonan dollarin tutkimusrahoituksesta Yhdysvaltain puolustusministeriön kanssa25.10.2022 09:00:00 EEST | Tiedote

Medicortex Finland Oyj, tapaturmaisten aivovammojen diagnostiikkaa ja hoitoa kehittävä turkulainen bioteknologiayhtiö, tiedottaa, että Yhdysvaltain puolustusministeriö (US Department of Defense, ”DoD”) on myöntänyt yhtiölle noin 2 miljoonan dollarin tutkimusrahoituksen lievän tapaturmaisen aivovamman ja aivotärähdyksen havaitsevan pikatestin kehittämiseen.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom